These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2320 related items for PubMed ID: 28595656

  • 1. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.
    Mol Cancer; 2017 Jun 08; 16(1):102. PubMed ID: 28595656
    [Abstract] [Full Text] [Related]

  • 2. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B, Ritt DA, Morrison DK, Der CJ, Cox AD.
    J Biol Chem; 2016 Aug 19; 291(34):17804-15. PubMed ID: 27226552
    [Abstract] [Full Text] [Related]

  • 3. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R.
    Pharmacol Res; 2018 Sep 19; 135():239-258. PubMed ID: 30118796
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 19; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 19; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 15. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
    Packer LM, East P, Reis-Filho JS, Marais R.
    Pigment Cell Melanoma Res; 2009 Dec 19; 22(6):785-98. PubMed ID: 19682280
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK.
    Oncotarget; 2015 Dec 01; 6(38):40535-56. PubMed ID: 26497853
    [Abstract] [Full Text] [Related]

  • 19. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 20. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 15; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 116.